Effects of etelcalcetide and cinacalcet on bone mineral density in patients with secondary hyperparathyroidism

Effects of etelcalcetide and cinacalcet on bone mineral density in patients with secondary hyperparathyroidism - Effects of etelcalcetide and cinacalcet on bone mineral density

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027453

Enrollment

Registered

2017-05-23

Start date

2017-05-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients on hemodialysis complicated with secondary hyperparathyroidism

Interventions

etelcalcetide dosage (2.5 - 15mg/every hemodialysis session) 12 months cinacalcet dosage (12.5 - 100mg/day) 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Maintenance hemodialysis patients with secondary hyperparathyroidism whose iPTH levels are higher than 240pg/ml despite the administration of maxacalcitol 2.5-5 micro g/every hemodialysis session.

Exclusion criteria

Exclusion criteria: Nothing paticular.

Design outcomes

Primary

Measure	Time frame
Bone mineral density (0, 6, 12 months) BAP, TRACP (0, 6, 12 months)	—

Secondary

Measure	Time frame
Ca, P, iPTH (once a month)	—

Countries

Japan

Contacts

Public ContactTakahiro Yajima

Matsunami general hospital Department of Nephrology

yajima5639@gmail.com058-388-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026